Liver Cancer Therapeutics Market to Witness Substantial Rate of Growth until 2025
Increasing prevalence of liver cancer among population across
the globe to drive liver cancer therapeutics market
According
to TechSci Research report, “Global Liver
Cancer Therapeutics Market By Cancer Type (Hepatocellular Carcinoma,
Cholangiocarcinoma, Others), By Therapy (Targeted Therapy, Radiation Therapy,
Immunotherapy, Chemotherapy, Others), By Equipment (Computed Radiography,
Radiofrequency Equipment, Others), By Age (0-18, 18-35, 35-50, 50+), By Factors
(Chronic Infection with HBV Or HCV, Cirrhosis, Inherited Liver Disease,
Diabetes, Others), By Route of Administration (Oral, Intra-Venous,
Intra-Arterial, Intra-Tumoral, Intra-Portal, Intra-Splenic, Intra-Biliary), By
Region, Forecast & Opportunities, 2025”, the global liver cancer therapeutics market is expected to
witness a robust CAGR during the forecast period owing to factors like rising
prevalence of liver cancer and development of novel innovative therapeutic
drugs, increase in awareness among people. Liver cancer accounts for the third
foremost reason for deaths associated with cancer around the world. Changes in
current lifestyle increases the risk factors that contribute to liver cancer. Scientists
around the world are working on research activities for developing novel
treatments for liver cancer, which is forecast to drive the market for liver
cancer therapeutics.
However, high capital investment, stringent drug
approval process, high research & development cost and adverse side-effects
of cancer treatment medications are factors which might hinder the growth of liver
cancer therapeutics market.
Browse
XX market data Tables and XX Figures spread through XXX
Pages and an in-depth TOC on" Global
Liver Cancer Therapeutics Market "
https://www.techsciresearch.com/report/liver-cancer-therapeutics-market/4667.html
The global
liver cancer therapeutics market is segmented based on cancer type, therapy,
equipment, age, factors, route of administration, distribution channel and region.
Based on cancer type, the market is segmented into hepatocellular carcinoma,
cholangiocarcinoma, hepatoblastoma, angiosarcoma and liver metastasis. The
hepatocellular carcinoma segment accounted for the largest market share in 2019
owing to its high prevalence, especially in Asian and African nations. Based on
therapy, the market is segmented into targeted therapy, radiation therapy,
immunotherapy, chemotherapy, radiofrequency ablation, microwave ablation,
embolization & chemoembolization and surgery. Among them, the targeted
therapy is anticipated to be the largest segment until 2025 as it is the only
approved targeted therapeutic treatment that is available for the treatment of
the advanced stage liver cancer. This therapy uses tyrosine kinase inhibitors
which inhibit the several kinase proteins that stimulate cancer cell growth.
Major players operating in the global liver
cancer therapeutics market include Bayer AG, Alnylam
Pharmaceuticals Inc., F. Hoffmann-La Roche AG , Bristol-Myers Squibb Co, Eisai
Co., Ltd. , Pfizer Inc., Exelixis, Inc., Merck & Co. Inc., Celsion
Corporation , ArQule Inc., Johnson & Johnson, Novartis, Sanofi, Eli Lily,
Perkin Elmer, Sunpharma, AbbVie, Amgen, AstraZeneca, Philips Healthcare and
others. The market players are focusing on research and development activities
to bring innovative treatments for liver cancer. Added to this, government
funding is also encouraging the R&D activities, which is propelling the
market growth across the globe.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4667
Customers can also request for 10% free customization on
this report.
“Aging population and unmet requirements for liver
cancer treatment accounts for the growth of global liver cancer therapeutics market. Today, variety of
treatment options are available in the market. However, increasing prevalence
of different types of liver cancer demands for more innovative drugs and
treatments. Moreover, the companies need to invest more in R&D activities
for further expansion of their market shares and to build a strong foothold,
globally.,” said Mr. Karan Chechi, Research Director with TechSci Research, a
research based global management consulting firm.
“Global Liver Cancer Therapeutics Market By Cancer
Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Others), By Therapy
(Targeted Therapy, Radiation Therapy, Immunotherapy, Chemotherapy, Others), By Equipment
(Computed Radiography, Radiofrequency Equipment, Others), By Age (0-18, 18-35,
35-50, 50+), By Factors (Chronic Infection with HBV Or HCV, Cirrhosis,
Inherited Liver Disease, Diabetes, Others), By Route of Administration (Oral,
Intra-Venous, Intra-Arterial, Intra-Tumoral, Intra-Portal, Intra-Splenic,
Intra-Biliary), By Region, Forecast & Opportunities, 2025” has evaluated the future growth potential of liver
cancer therapeutics market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges and opportunities in global liver
cancer therapeutics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]